• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Surges Over 200 Points; Pfizer Issues Weak Forecast

    1/31/23 2:36:33 PM ET
    $APCX
    $ATCX
    $CNTX
    $IP
    Computer Software: Prepackaged Software
    Technology
    Precious Metals
    Basic Materials
    Get the next $APCX alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Tuesday.

    The Dow traded up 0.63% to 33,931.13 while the NASDAQ rose 1.20% to 11,529.99. The S&P 500 also rose, gaining, 0.93% to 4,055.00.

    Check This Out: Over $5M Bet On Uber Technologies? Check Out These 4 Stocks Insiders Are Buying

     

    Leading and Lagging Sectors

    • Materials shares rose by 1.7% on Tuesday. Meanwhile, top gainers in the sector included Lithium Americas Corp. (NYSE:LAC), up 14%, and International Paper Company (NYSE:IP), up 10%.
    • In trading on Tuesday, utilities shares fell by 0.4%.

     

    Top Headline

    Pfizer Inc (NYSE:PFE) posted upbeat earnings for its fourth quarter, but issued weak guidance.

    Pfizer reported a Q4 adjusted EPS of $1.14, up 45% Y/Y, well ahead of the consensus of $1.05. The company achieved revenues of $24.29 billion, up 2% and 13% on an operational basis, marginally missing the Wall Street estimate of $24.32 billion.

    The company expects adjusted EPS guidance of $3.25-$3.45, down from $6.58 in 2022 and the consensus of $4.44.

     

    Equities Trading UP

    • Motorsport Games Inc. (NASDAQ:MSGM) shares shot up 689% to $20.75. The company announced a debt-for-equity exchange with Motorsport Network. Also, Investor Mike Zoi reported purchase of 338,983 shares of Motorsport Games at an average price of $2.95 per share in Form 4 Filing.
    • Shares of Atlas Technical Consultants, Inc. (NASDAQ:ATCX) got a boost, shooting 120% to $12.06 after the company agreed to be acquired by GI Partners for $12.25 per share in cash.
    • Context Therapeutics Inc. (NASDAQ:CNTX) shares were also up, gaining 53% to $1.0407 after the company announced its clinical trial collaborator, Stemline Therapeutics, received approval from the FDA for ORSERDU in ER+, HER2-, ESR1-mutated breast cancer.

     

    Equities Trading DOWN

    • Nuvve Holding Corp. (NASDAQ:NVVE) shares tumbled 40% to $1.38 after the company filed for common stock offering of up to $25 million.
    • Shares of AppTech Payments Corp. (NASDAQ:APCX) were down 20% to $4.2899.
    • AppTech Payments reported pricing of $5 million registered direct offering and concurrent private placement.
    • Woodward, Inc. (NASDAQ:WWD) was down, falling 10% to $97.99 following weak quarterly earnings.

    Also Check This Out: Ethereum Drops Below $1,600; BitDAO, Helium Among Top Losers

     

    Commodities

    In commodity news, oil traded up 1.3% to $78.92 while gold traded up 1.2% at $1,945.10.

    Silver traded up 0.4% to $23.83 on Tuesday while copper rose 0.6% to $4.2275.

     

    Euro zone

    European shares were mixed today. The eurozone’s STOXX 600 fell 0.26%, London’s FTSE 100 fell 0.17% while Spain’s IBEX 35 Index fell 0.17%. The German DAX gained 0.01% French CAC 40 rose 0.01% and Italy’s FTSE MIB Index rose 1%.

    The Eurozone economy expanded by 0.1% during the final quarter of 2022, compared to a 0.3% growth in the prior three-month period. Consumer credit in the UK rose by GBP 0.493 billion in December versus a revised GBP 1.488 billion increase in the prior month. The unemployment rate in Germany came in unchanged for a fifth straight month at 5.5% in January, while unemployment rate in Italy also held steady at 7.8% in December. Retail sales in Germany dropped 5.3% month-over-month in December.

    Producer prices in the French domestic markets increased 1.4% month-over-month in December, while annual inflation rate in the country rose to 6% in January from 5.9% in the previous month. French economy expanded 0.1% on quarter in the fourth quarter.

     

    Asia Pacific Markets

    Asian markets closed mostly lower on Tuesday, with Japan’s Nikkei 225 dropping 0.39%, Hong Kong’s Hang Seng Index dropping 1.03% and China’s Shanghai Composite Index falling 0.42%. India’s S&P BSE Sensex gained 0.21%.

    Japan's housing starts dropped by 1.7% year-over-year in December, while consumer confidence index in the country rose to 31.0 in January from 30.3 in the previous month. Retail sales in Japan climbed 3.8% from a year ago in December, while industrial production fell 0.1% month-over-month in December. Japan’s unemployment rate came in unchanged at 2.5% for December.

    Singapore’s unemployment rate fell to 2.0% in Q4. The NBS Composite PMI Output Index for China climbed to 52.9 in January from 42.6 in the earlier month.

     

    Economics

    • The Chicago PMI in the US dropped to 44.3 points in January from 44.9 in December.
    • The S&P CoreLogic Case-Shiller 20-city home price index increased 6.8% year-over-year in November.
    • The FHFA house price index dropped 0.1% from a month ago in November.

    Now Read This: Investor Optimism Declines Ahead Of Fed's Rate Decision

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 104,183,560 cases with around 1,132,710 deaths. India confirmed a total of at least 44,682,780 cases and 530,740 deaths, while France reported over 39,517,450 COVID-19 cases with 164,170 deaths. In total, there were at least 675,120,840 cases of COVID-19 worldwide with more than 6,761,620 deaths.

    Get the next $APCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APCX
    $ATCX
    $CNTX
    $IP

    CompanyDatePrice TargetRatingAnalyst
    International Paper Company
    $IP
    2/2/2026$44.00Buy → Neutral
    UBS
    Atlas Critical Minerals Corporation
    $ATCX
    1/30/2026$42.00Buy
    Alliance Global Partners
    International Paper Company
    $IP
    1/30/2026$40.00Underweight → Equal Weight
    Wells Fargo
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Woodward Inc.
    $WWD
    1/5/2026Hold → Buy
    Melius
    Pfizer Inc.
    $PFE
    12/2/2025$26.00Neutral
    Citigroup
    International Paper Company
    $IP
    11/24/2025$44.00Underperform → Outperform
    BNP Paribas Exane
    Lithium Americas Corp.
    $LAC
    11/19/2025Sell → Hold
    Canaccord Genuity
    More analyst ratings

    $APCX
    $ATCX
    $CNTX
    $IP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Connor Christopher M bought $1,009,250 worth of shares (25,000 units at $40.37) (SEC Form 4)

    4 - INTERNATIONAL PAPER CO /NEW/ (0000051434) (Issuer)

    2/2/26 5:30:10 PM ET
    $IP
    Paper
    Basic Materials

    Chief Executive Officer Silvernail Andrew K bought $1,998,965 worth of shares (50,000 units at $39.98) (SEC Form 4)

    4 - INTERNATIONAL PAPER CO /NEW/ (0000051434) (Issuer)

    1/30/26 4:47:45 PM ET
    $IP
    Paper
    Basic Materials

    Director Delta John bought $13,020 worth of shares (5,000 units at $2.60), increasing direct ownership by 71% to 12,000 units (SEC Form 4)

    4 - Motorsport Games Inc. (0001821175) (Issuer)

    12/12/25 5:31:22 PM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    $APCX
    $ATCX
    $CNTX
    $IP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

    Submission is to expand HYMPAVZI indication to the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) without inhibitors If approved, HYMPAVZI would become the first non-factor prophylactic treatment available for children aged 6 to 11 years with hemophilia B Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patient

    2/6/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

    Program offers significant savings on over 30 brands spanning women's health, migraine, arthritis, rare disease and more Affirms Pfizer's commitment to reduce drug costs for millions of Americans through historic agreement with Trump administration Pfizer Inc. (NYSE:PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer's broader landmark Most Favored Nation (MFN) agreement with the U.S. government enabling patients to pay lower prices for

    2/5/26 7:09:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

    Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc

    2/3/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APCX
    $ATCX
    $CNTX
    $IP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohn John D exercised 2,250 units of Woodward at a strike of $62.57 and sold $831,645 worth of Woodward (2,250 units at $369.62) (SEC Form 4)

    4 - Woodward, Inc. (0000108312) (Issuer)

    2/5/26 5:28:05 PM ET
    $WWD
    Industrial Machinery/Components
    Energy

    SVP, GC and Corp. Secretary Saab Joseph R. covered exercise/tax liability with 1,614 shares (SEC Form 4)

    4 - INTERNATIONAL PAPER CO /NEW/ (0000051434) (Issuer)

    2/3/26 7:22:22 PM ET
    $IP
    Paper
    Basic Materials

    Exec. VP & President Nicholls Timothy S covered exercise/tax liability with 440 shares, decreasing direct ownership by 0.18% to 246,285 units (SEC Form 4)

    4 - INTERNATIONAL PAPER CO /NEW/ (0000051434) (Issuer)

    2/3/26 7:20:51 PM ET
    $IP
    Paper
    Basic Materials

    $APCX
    $ATCX
    $CNTX
    $IP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Int'l Paper downgraded by UBS with a new price target

    UBS downgraded Int'l Paper from Buy to Neutral and set a new price target of $44.00

    2/2/26 6:49:16 AM ET
    $IP
    Paper
    Basic Materials

    Alliance Global Partners initiated coverage on Atlas Critical Minerals with a new price target

    Alliance Global Partners initiated coverage of Atlas Critical Minerals with a rating of Buy and set a new price target of $42.00

    1/30/26 7:03:21 AM ET
    $ATCX
    Precious Metals
    Basic Materials

    Int'l Paper upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Int'l Paper from Underweight to Equal Weight and set a new price target of $40.00

    1/30/26 6:40:29 AM ET
    $IP
    Paper
    Basic Materials

    $APCX
    $ATCX
    $CNTX
    $IP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APCX
    $ATCX
    $CNTX
    $IP
    SEC Filings

    View All

    SEC Form 10-Q filed by Woodward Inc.

    10-Q - Woodward, Inc. (0000108312) (Filer)

    2/4/26 1:07:13 PM ET
    $WWD
    Industrial Machinery/Components
    Energy

    Amendment: AppTech Payments Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K/A - AppTech Payments Corp. (0001070050) (Filer)

    2/3/26 5:22:45 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    SEC Form SCHEDULE 13G filed by Context Therapeutics Inc.

    SCHEDULE 13G - Context Therapeutics Inc. (0001842952) (Subject)

    2/3/26 4:41:54 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APCX
    $ATCX
    $CNTX
    $IP
    Leadership Updates

    Live Leadership Updates

    View All

    TTM Technologies, Inc. Appoints Two New Independent Directors

    SANTA ANA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- TTM Technologies, Inc. (NASDAQ:TTMI), a leading global manufacturer of technology products, including mission systems, radio frequency ("RF") components and RF microwave/microelectronic assemblies, and technologically advanced interconnect solutions, including printed circuit boards ("PCB") and substrates, today announced that, after long and distinguished careers with TTM, Thomas Edman, the Company's former President and Chief Executive Officer and a current Class I member of the Board of Directors (the "Board"), and John Mayer, a current Class III member of the Board, will retire from the Board effective as of May 7, 2026, immediately

    2/2/26 7:00:00 AM ET
    $CACI
    $DCO
    $TTMI
    EDP Services
    Technology
    Military/Government/Technical
    Industrials

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Lithium Americas to Join the S&P/TSX Composite Index

    (All amounts in US$ unless otherwise indicated) Lithium Americas Corp. (TSX:LAC) (NYSE:LAC) ("Lithium Americas" or the "Company") announced that, as disclosed by S&P Dow Jones Indices on December 5, 2025, the Company's common shares will be added to the S&P/TSX Composite Index, effective prior to the open of trading on Monday, December 22, 2025. The S&P/TSX Composite Index is Canada's premier equity benchmark and includes the largest and most actively traded companies on the Toronto Stock Exchange. Jonathan Evans, President and CEO said, "Our inclusion on the S&P/TSX Composite Index demonstrates the significant progress Lithium Americas has made as we advance Thacker Pass toward productio

    12/8/25 7:00:00 AM ET
    $LAC
    Metal Mining
    Basic Materials

    $APCX
    $ATCX
    $CNTX
    $IP
    Financials

    Live finance-specific insights

    View All

    Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

    Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc

    2/3/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Woodward Reports Strong First Quarter Fiscal Year 2026 Results

    FORT COLLINS, Colo., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Woodward, Inc. (NASDAQ:WWD) today reported financial results for its first quarter ended December 31, 2025. All amounts are presented on an as reported (U.S. GAAP) basis unless otherwise indicated. All per share amounts are presented on a fully diluted basis. All comparisons are made to the same period of the prior year unless otherwise stated. All references to years are references to the Company's fiscal year unless otherwise stated. First Quarter Overview   First Quarter 2026Net sales $996M, +29%Net earnings $134M, +54%Earnings per share (EPS) $2.17, +53%Net cash provided by operating activities $114M, +$80MFree cash flow1 $70M, +

    2/2/26 4:00:00 PM ET
    $WWD
    Industrial Machinery/Components
    Energy

    Woodward Increases Quarterly Dividend by 14 Percent

    FORT COLLINS, Colo., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Woodward, Inc. (NASDAQ:WWD) today announced that its Board of Directors declared a cash dividend of $0.32 per share, an increase of 14 percent from the prior quarter's dividend of $0.28 per share. The dividend will be payable on March 5, 2026, for stockholders of record as of February 19, 2026. About Woodward, Inc. Woodward is the global leader in the design, manufacture, and service of energy conversion and control solutions for the aerospace and industrial equipment markets. Our purpose is to design and deliver energy control solutions our partners count on to power a clean future. Our innovative fluid, combustion, electrical, pro

    2/2/26 7:00:00 AM ET
    $WWD
    Industrial Machinery/Components
    Energy

    $APCX
    $ATCX
    $CNTX
    $IP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:31:29 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Context Therapeutics Inc.

    SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:05:15 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 4:52:28 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care